Inclusion Criteria

1. Male or female patients, 18 years or older
2. Patients who are registered in the GEDII Registry
3. Patients with moderate to severe active Crohn's disease or moderate to severe active Ulcerative Colitis
4. Patients receiving anti-TNF-alfa agents (adalimumab/golimumab or infliximab/vedoluzimab) according to the local approved label, including:
   - ❖ Biologic-naïve patients initiating induction with adalimumab/golimumab or infliximab/vedoluzimab at time of inclusion in the study
   - ❖ Patients already under maintenance treatment with adalimumab/golimumab or infliximab/vedoluzimab at time of inclusion in the study
5. Patients who gave their informed consent.

Exclusion Criteria

1. Patients who are not eligible for therapy with anti-TNF-alfa (adalimumab, golimumab, infliximab) or vedoluzimab
1. Patients who are being treated with any investigational agent
2. Patients who are not willing to comply with routine clinical appointments.

Laboratory Testing

Serum Samples

- For all time points, marked in the chronogram, collect 5 mL of blood to a serum gel tube
- Blood must be left for 1 hour at room temperature to assure coagulation
- Centrifuge at 3000 rpm, for 10 min
- Collect serum to two cryovials
- Identify cryovials with the label provided in the kit
- Freeze and store serum samples at -20ºC until refrigerated transport is provided

Fecal Samples

- Each sample should be collected with the EASYSample collection Kit. The tube must be identified with the label provided in the kit.
- Send samples to central laboratory within 48 hours
- **Contact GEDII for transport**

For any study related questions, please contact:

Sandra Dias

E-mail: gedi@med.up.pt
Phone number: 912583273

DIRECT

Title: Study to investigate the correlation of fecal calprotectin with serum Drug levels and development of an antI-dRug antibodiEs among adult patients with inflammatory bowel disease reCeiving anti-TNF-alfa treatment or Vedoluzimab treatment - Direct Study

Study sponsor: Grupo de Estudo da Doença Inflamatória Intestinal (GEDII)

Name of Scientific Coordinator: Prof. Fernando Magro

Primary Objectives

Among biologic-naïve and non-naïve patients with CD or patients with UC registered in the GEDII Registry:

- To explore the association of fecal calprotectin levels with serum adalimumab/golimumab levels throughout a period of 2 years since the start of observation period.
- To explore the association of fecal calprotectin levels with the development of anti-adalimumab/anti-golimumab antibodies throughout a period of 2 years since the start of observation period.
- To explore the association of fecal calprotectin levels with serum IFX/vedoluzimab levels throughout a period of 2 years since the start of observation period.
- To explore the association of fecal calprotectin levels with the development of anti-IFX/anti-vedoluzimab antibodies throughout a period of 2 years since the start of observation period.

Chronogram A (CD or UC patients receiving Adalimumab or UC patients receiving Golimumab)

	Adalimumab / Golimumab											
	Induction period			Maintenance period data collection time points (24-month follow up)								
Information to be collected	**Day1 or basal**	**W 2**	**W 6**	**W 12**	**W 24**	**W 36**	**W 48**	**W 60**	**W 72**	**W 84**	**W 96**	**Or comple -tion of Fup3**
Date of birth	X[4]											
Sex	X[4]											
Height	X[4]											
Weight	X	X	X	X	X	X	X	X	X	X	X	X
BMI	X	X	X	X	X	X	X	X	X	X	X	X
Smoking status	X[4]											
Medical history	X[4]											
Comorbidities	X	X	X	X	X	X	X	X	X	X	X	X
Disease presentation	X[4]											
Diagnosis (UC or CD) – location, steroid behavior, prognostic classification)	X[4]											
Clinical activity (HBI / Partial Mayo)	X	X	X	X	X	X	X	X	X	X	X	X
Dose of adalimumab/ golimumab administered	X	X	X	X	X	X	X	X	X	X	X	X
Concomitant therapies	X	X	X	X	X	X	X	X	X	X	X	X
Routine laboratory parameters	X	X	X	X	X	X	X	X	X	X	X	X
Serum levels (adalimumab/ golimumab)[1]	X	X	X	X	X	X	X	X	X	X	X	X
Anti-drug antibodies (adalimumab/ golimumab)[1]	X	X	X	X	X	X	X	X	X	X	X	X
Fecal sample (calprotectin levels)[2]	X	X	X	X	X	X	X	X	X	X	X	X
Patient reported outcomes (HBI or Partial Mayo)	X	X	X	X	X	X	X	X	X	X	X	X

The data collection time points maintenance with adalimumab/ golimumab are expected every 12 weeks until completing the 24-month follow up period

[1] Blood sample to be collected prior to each infusion of adalimumab/ golimumab at the scheduled appointment (approximately every 12 weeks during maintenance period). Sample will be analyzed by Central Laboratory.

[2]Stool sample to be collected prior to each infusion of adalimumab/ golimumab at the scheduled appointment (approximately every 12 weeks during maintenance period). Sample will be analyzed by Central Laboratory.

[3]Patients in maintenance with adalimumab/ golimumab at study inclusion will be followed every 12 weeks until completing the 24-month follow up period.

[4]Basal data to be collected, regardless of the patient's treatment phase at study inclusion. W = week. HBI = Harvey Bradshaw Index.

Chronogram B (CD or UC patients receiving Infliximab or Vedoluzimab)

	Infliximab / Vedoluzimab															
	Induction period			Maintenance period - data collection time points (24-month follow up)												
Information to be collected	**Day1 or basal**	**W 2**	**W 6**	**W 14**	**W 22**	**W 30**	**W 38**	**W 46**	**W 54**	**W 62**	**W 70**	**W 78**	**W 86**	**W 94**	**W 102**	**Or comple -tion of Fup[3]**
Date of birth	X[4]															
Sex	X[4]															
Height	X[4]															
Weight	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
BMI	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Smoking status	X[4]															
Medical history	X[4]															
Comorbidities	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Disease presentation	X[4]															
Diagnosis (UC or CD) – location, steroid behavior, prognostic classification)	X[4]															
Clinical activity (HBI / Partial Mayo)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Dose of IFX/Vedo administered	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Concomitant therapies	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Routine laboratory parameters	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Serum IFX/Vedo levels[1]	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Anti-IFX/anti-Vedo antibodies[1]	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Fecal sample (calprotectin levels)[2]	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Patient reported outcomes (HBI or Partial Mayo)	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X

The data collection time points during maintenance with infliximab/ vedoluzimab are expected every 8 weeks (or every 6 weeks, if required) until completing the 24-month follow up period.

[1] Blood sample to be collected prior to each infusion of IFX/ Vedo at the scheduled appointment (approximately every 8/6 weeks).Sample will be analyzed by Central Laboratory.

[2] Stool sample to be collected prior to each infusion of IFX/ Vedo at the scheduled appointment (approximately every 8/6 weeks).Sample will be analyzed by Central Laboratory

[3] Patients in maintenance with infliximab/ vedoluzimab at study inclusion will be followed every 8/6 weeks until completing the 24-month follow up period;

[4] Basal data to be collected, regardless of the patient's treatment phase at study inclusion.

W = week; IFX = infliximab, HBI = Harvey Bradshaw Index. Vedo = Vedoluzimab